Novavax vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Novavax Inc (NVAX)

Q3 202622 Jun – 30 Aug 2026

▲3▼1

Novavax's partner-led vaccine model gains traction as guidance rises

2026 revenue guidance raised on Matrix-M demand Novavax lifted its full-year 2026 revenue outlook to $235-$275 million, citing strong demand for its Matrix-M adjuvant from partners. It also said it is on track to cut operating costs by about 90% from peak levels and still aims for profitability as early as 2028. Higher expected revenue and lower costs make the company's path to making money look more believable, which supports the stock.
This is the period's biggest company-specific event and directly changes the earnings outlook that drives the share price.
Partner approvals for Nuvaxovid secure royalties and milestones Sanofi and Takeda won approvals for the updated Nuvaxovid shot in the U.S., European Union, and Japan for the 2026-2027 season. Because partners handle sales, Novavax earns royalties and annual milestone payments without paying for its own sales force. That turns vaccine demand into cash for Novavax with little added cost, which is good for the stock.
It shows the partner-based business model converting into actual cash flow, a core reason investors hold NVAX.
Sanofi partnership advances toward $125 million milestone Sanofi is in advanced regulatory talks for a Phase 3 combination COVID-and-flu vaccine study, which would trigger a $125 million payment to Novavax. A separate $75 million manufacturing transfer milestone is expected by mid-2027, extending the company's cash runway into 2029. These payments reduce the risk of running short of money, which supports the share price.
It quantifies near-term cash coming in and lowers the biggest risk for a company not yet profitable.
Moderna's new COVID and mRNA flu approvals raise competition Moderna won FDA approval for updated COVID shots and the first mRNA flu vaccine for adults 50 and over. That widens Moderna's respiratory lineup and could take shelf space and market share from Novavax's partner-led Nuvaxovid, especially if pharmacies stock more Moderna products. More competition in the same seasonal market can pressure Novavax's royalty revenue and stock.
It is the main counterweight this period, showing a rival strengthening in Novavax's core market.

July 202622 Jun – 30 Aug 2026

▲3▼1

Novavax's partner-led vaccine model gains traction as guidance rises

2026 revenue guidance raised on Matrix-M demand Novavax lifted its full-year 2026 revenue outlook to $235-$275 million, citing strong demand for its Matrix-M adjuvant from partners. It also said it is on track to cut operating costs by about 90% from peak levels and still aims for profitability as early as 2028. Higher expected revenue and lower costs make the company's path to making money look more believable, which supports the stock.
This is the period's biggest company-specific event and directly changes the earnings outlook that drives the share price.
Partner approvals for Nuvaxovid secure royalties and milestones Sanofi and Takeda won approvals for the updated Nuvaxovid shot in the U.S., European Union, and Japan for the 2026-2027 season. Because partners handle sales, Novavax earns royalties and annual milestone payments without paying for its own sales force. That turns vaccine demand into cash for Novavax with little added cost, which is good for the stock.
It shows the partner-based business model converting into actual cash flow, a core reason investors hold NVAX.
Sanofi partnership advances toward $125 million milestone Sanofi is in advanced regulatory talks for a Phase 3 combination COVID-and-flu vaccine study, which would trigger a $125 million payment to Novavax. A separate $75 million manufacturing transfer milestone is expected by mid-2027, extending the company's cash runway into 2029. These payments reduce the risk of running short of money, which supports the share price.
It quantifies near-term cash coming in and lowers the biggest risk for a company not yet profitable.
Moderna's new COVID and mRNA flu approvals raise competition Moderna won FDA approval for updated COVID shots and the first mRNA flu vaccine for adults 50 and over. That widens Moderna's respiratory lineup and could take shelf space and market share from Novavax's partner-led Nuvaxovid, especially if pharmacies stock more Moderna products. More competition in the same seasonal market can pressure Novavax's royalty revenue and stock.
It is the main counterweight this period, showing a rival strengthening in Novavax's core market.

Latest22 Jun – 30 Aug 2026

▲3▼1

Novavax's partner-led vaccine model gains traction as guidance rises

2026 revenue guidance raised on Matrix-M demand Novavax lifted its full-year 2026 revenue outlook to $235-$275 million, citing strong demand for its Matrix-M adjuvant from partners. It also said it is on track to cut operating costs by about 90% from peak levels and still aims for profitability as early as 2028. Higher expected revenue and lower costs make the company's path to making money look more believable, which supports the stock.
This is the period's biggest company-specific event and directly changes the earnings outlook that drives the share price.
Partner approvals for Nuvaxovid secure royalties and milestones Sanofi and Takeda won approvals for the updated Nuvaxovid shot in the U.S., European Union, and Japan for the 2026-2027 season. Because partners handle sales, Novavax earns royalties and annual milestone payments without paying for its own sales force. That turns vaccine demand into cash for Novavax with little added cost, which is good for the stock.
It shows the partner-based business model converting into actual cash flow, a core reason investors hold NVAX.
Sanofi partnership advances toward $125 million milestone Sanofi is in advanced regulatory talks for a Phase 3 combination COVID-and-flu vaccine study, which would trigger a $125 million payment to Novavax. A separate $75 million manufacturing transfer milestone is expected by mid-2027, extending the company's cash runway into 2029. These payments reduce the risk of running short of money, which supports the share price.
It quantifies near-term cash coming in and lowers the biggest risk for a company not yet profitable.
Moderna's new COVID and mRNA flu approvals raise competition Moderna won FDA approval for updated COVID shots and the first mRNA flu vaccine for adults 50 and over. That widens Moderna's respiratory lineup and could take shelf space and market share from Novavax's partner-led Nuvaxovid, especially if pharmacies stock more Moderna products. More competition in the same seasonal market can pressure Novavax's royalty revenue and stock.
It is the main counterweight this period, showing a rival strengthening in Novavax's core market.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest21 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.